Oligomerization of the hydrophobic heptad repeat of gp41 - PubMed (original) (raw)
Oligomerization of the hydrophobic heptad repeat of gp41
H B Bernstein et al. J Virol. 1995 May.
Abstract
The transmembrane protein of human immunodeficiency virus type 1 (HIV-1) contains a leucine zipper-like (hydrophobic heptad) repeat which has been predicted to form an amphipathic alpha helix. To evaluate the potential of the hydrophobic heptad repeat to induce protein oligomerization, this region of gp41 has been cloned into the bacterial expression vector pRIT2T. The resulting plasmid, pRIT3, expresses a fusion protein consisting of the Fc binding domain of monomeric protein A, a bacterial protein, and amino acids 538 to 593 of HIV-1 gp41. Gel filtration chromatography demonstrated the presence of oligomeric forms of the fusion protein, and analytical centrifugation studies confirmed that the chimeric protein formed a higher-order multimer that was greater than a dimer. Thus, we have identified a region of HIV-1 gp41 which is capable of directing the oligomerization of a fusion protein containing monomeric protein A. Point mutations, previously shown to inhibit the biological activity of the HIV-1 envelope glycoprotein, have been engineered into the segment of gp41 contained in the fusion protein, and expressed mutant proteins were purified and analyzed via fast protein liquid chromatography. A point mutation in the heptad repeat, which changed the central isoleucine to an alanine, caused a significant (> 60%) decrease in oligomerization, whereas changing the central isoleucine to aspartate or proline resulted in almost a complete loss of oligomerization. Deletions of one, two, or three amino acids following the first isoleucine also resulted in a profound decrease in oligomerization. The inhibitory effects of the mutations on oligomer formation correlated with the effects of the same mutations on envelope glycoprotein-mediated fusion. A possible role of the leucine zipper-like region in the fusion process and in an oligomerization event distinct from assembly of the envelope glycoprotein complex is discussed.
Similar articles
- Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence.
Poumbourios P, Wilson KA, Center RJ, El Ahmar W, Kemp BE. Poumbourios P, et al. J Virol. 1997 Mar;71(3):2041-9. doi: 10.1128/JVI.71.3.2041-2049.1997. J Virol. 1997. PMID: 9032336 Free PMC article. - Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41.
Shugars DC, Wild CT, Greenwell TK, Matthews TJ. Shugars DC, et al. J Virol. 1996 May;70(5):2982-91. doi: 10.1128/JVI.70.5.2982-2991.1996. J Virol. 1996. PMID: 8627774 Free PMC article. - Mutations in the leucine zipper-like heptad repeat sequence of human immunodeficiency virus type 1 gp41 dominantly interfere with wild-type virus infectivity.
Chen SS, Lee SF, Hao HJ, Chuang CK. Chen SS, et al. J Virol. 1998 Jun;72(6):4765-74. doi: 10.1128/JVI.72.6.4765-4774.1998. J Virol. 1998. PMID: 9573241 Free PMC article. - Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein.
Chen SS, Lee CN, Lee WR, McIntosh K, Lee TH. Chen SS, et al. J Virol. 1993 Jun;67(6):3615-9. doi: 10.1128/JVI.67.6.3615-3619.1993. J Virol. 1993. PMID: 8497069 Free PMC article. - Allosteric modulation of protein oligomerization: an emerging approach to drug design.
Gabizon R, Friedler A. Gabizon R, et al. Front Chem. 2014 Mar 24;2:9. doi: 10.3389/fchem.2014.00009. eCollection 2014. Front Chem. 2014. PMID: 24790978 Free PMC article. Review.
Cited by
- ADS-J21 is a novel HIV-1 entry inhibitor targeting gp41.
Liang R, Dou D, Wang C, Huo S, Wu Y, Wang J, Yu Z, Zhang S, Xu J, Liu Y, Liu P, Jiang S, Yu F. Liang R, et al. Curr Res Microb Sci. 2024 Jul 9;7:100260. doi: 10.1016/j.crmicr.2024.100260. eCollection 2024. Curr Res Microb Sci. 2024. PMID: 39129758 Free PMC article. - Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.
Rimsky LT, Shugars DC, Matthews TJ. Rimsky LT, et al. J Virol. 1998 Feb;72(2):986-93. doi: 10.1128/JVI.72.2.986-993.1998. J Virol. 1998. PMID: 9444991 Free PMC article. - Amino acid residues in the cytoplasmic domain of the Mason-Pfizer monkey virus glycoprotein critical for its incorporation into virions.
Song C, Micoli K, Bauerova H, Pichova I, Hunter E. Song C, et al. J Virol. 2005 Sep;79(18):11559-68. doi: 10.1128/JVI.79.18.11559-11568.2005. J Virol. 2005. PMID: 16140733 Free PMC article. - Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains.
Dave RS, Pomerantz RJ. Dave RS, et al. J Virol. 2004 Dec;78(24):13687-96. doi: 10.1128/JVI.78.24.13687-13696.2004. J Virol. 2004. PMID: 15564478 Free PMC article. - The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events.
Rosenberg AR, Delamarre L, Pique C, Pham D, Dokhélar MC. Rosenberg AR, et al. J Virol. 1997 Oct;71(10):7180-6. doi: 10.1128/JVI.71.10.7180-7186.1997. J Virol. 1997. PMID: 9311790 Free PMC article.
References
- AIDS Res Hum Retroviruses. 1989 Aug;5(4):431-40 - PubMed
- Nature. 1994 Sep 1;371(6492):37-43 - PubMed
- Eur J Biochem. 1972 Sep 25;29(3):579-84 - PubMed
- Methods Enzymol. 1979;61:103-24 - PubMed
- Science. 1986 Jan 24;231(4736):382-5 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources